Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases

Biochemical Society Transactions

Volumn 42, Issue 2, 2014, Pages 593-599

  Hölscher, Christian ^a  

^a LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

Memory; Neurodegeneration; Oxidative stress; Synaptic plasticity

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GROWTH FACTOR; INCRETIN; INSULIN; LIRAGLUTIDE; SIGNAL PEPTIDE;

ALZHEIMER DISEASE; BRAIN REGION; CELL REGENERATION; COGNITION; DEGENERATIVE DISEASE; DIABETES MELLITUS; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; HUMAN; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SYNAPTOGENESIS; ANIMAL; DRUG EFFECTS; METABOLISM; OXIDATIVE STRESS;

ALZHEIMER DISEASE; ANIMALS; HUMANS; INCRETINS; INSULIN; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEURONAL PLASTICITY; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 84896920228     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20140016     Document Type: Review

References (67)

1. Moroo, I., Yamada, T., Makino, H., Tooyama, I., McGeer, P.L., McGeer, E.G. and Hirayama, K. (1994) Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease. Acta Neuropathol. 87, 343-348 (Pubitemid 24091615)
2. Aviles-Olmos, I., Limousin, P., Lees, A. and Foltynie, T. (2013) Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain 136, 374-384
3. Strachan, M.W. (2005) Insulin and cognitive function in humans: experimental data and therapeutic considerations. Biochem. Soc. Trans. 33, 1037-1040
4. Haan, M.N. (2006) Therapy insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nat. Clin. Pract. Neurol. 2, 159-166
5. Luchsinger, J.A., Tang, M.X., Shea, S. and Mayeux, R. (2004) Hyperinsulinemia and risk of Alzheimer disease. Neurology 63, 1187-1192 (Pubitemid 39350015)
6. Ristow, M. (2004) Neurodegenerative disorders associated with diabetes mellitus. J. Mol. Med. 82, 510-529
7. Biessels, G.J., De Leeuw, F.E., Lindeboom, J., Barkhof, F. and Scheltens, P. (2006) Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus. J. Neurol. Neurosurg. Psychiatry 77, 304-307
8. Leibson, C.L., Rocca, W.A., Hanson, V.A., Cha, R., Kokmen, E., O'Brien, P.C. and Palumbo, P.J. (1997) Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am. J. Epidemiol. 145, 301-308 (Pubitemid 27082028)
9. Janson, J., Laedtke, T., Parisi, J.E., O'Brien, P., Petersen, R.C. and Butler, P.C. (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53, 474-481 (Pubitemid 38174565)
10. Ohara, T., Doi, Y., Ninomiya, T., Hirakawa, Y., Hata, J., Iwaki, T., Kanba, S. and Kiyohara, Y. (2011) Glucose tolerance status and risk of dementia in the community: the Hisayama Study. Neurology 77, 1126-1134
11. Steen, E., Terry, B.M., Rivera, E., Cannon, J.L., Neely, T.R., Tavares, R., Xu, X.J., Wands, J.R. and de la Monte, S.M. (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease: is this type 3 diabetes? J. Alzheimer's Dis. 7, 63-80 (Pubitemid 40387185)
12. Lester-Coll, N., Rivera, E.J., Soscia, S.J., Doiron, K., Wands, J.R. and de la Monte, S.M. (2006) Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J. Alzheimer's Dis. 9, 13-33
13. Bomfim, T.R., Forny-Germano, L., Sathler, L.B., Brito-Moreira, J., Houzel, J.C., Decker, H., Silverman, M.A., Kazi, H., Melo, H.M., McClean, P.L. et al. (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Aβ oligomers. J. Clin. Invest. 122, 1339-1353
14. Moloney, A.M., Griffin, R.J., Timmons, S., O'Connor, R., Ravid, R. and O'Neill, C. (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 31, 224-243
15. Talbot, K., Wang, H.Y., Kazi, H., Han, L.Y., Bakshi, K.P., Stucky, A., Fuino, R.L., Kawaguchi, K.R., Samoyedny, A.J., Wilson, R.S. et al. (2012) Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 122, 1316-1338
16. Morris, J.K., Zhang, H., Gupte, A.A., Bomhoff, G.L., Stanford, J.A. and Geiger, P.C. (2008) Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease. Brain Res. 1240, 185-195
17. Morris, J.K., Bomhoff, G.L., Stanford, J.A. and Geiger, P.C. (2010) Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet. Am. J. Physiol. Regul. Integr. Comp. Physiol. 299, R1082-R1090
18. Porter, D.W., Kerr, B.D., Flatt, P.R., Hölscher, C. and Gault, V.A. (2010) Four weeks administration of liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance. Diabetes Obes. Metab. 12, 891-899
19. Morris, J.K., Bomhoff, G.L., Gorres, B.K., Davis, V.A., Kim, J., Lee, P.P., Brooks, W.M., Gerhardt, G.A., Geiger, P.C. and Stanford, J.A. (2011) Insulin resistance impairs nigrostriatal dopamine function. Exp. Neurol. 231, 171-180
20. Stockhorst, U., de Fries, D., Steingrueber, H.J. and Scherbaum, W.A. (2004) Insulin and the CNS: effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans. Physiol. Behav. 83, 47-54 (Pubitemid 39387693)
21. Hoyer, S. (2004) Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur. J. Pharmacol. 490, 115-125
22. van Dam, P. and Aleman, A. (2004) Insulin-like growth factor-I, cognition and brain aging. Eur. J. Pharmacol. 490, 87-95
23. Freiherr, J., Hallschmid, M., Frey, 2nd, W.H., Brunner, Y.F., Chapman, C.D., Ḧolscher, C., Craft, S., De Felice, F.G. and Benedict, C. (2013) Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 27, 505-514
24. Watson, G.S. and Craft, S. (2004) Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. Eur. J. Pharmacol. 490, 97-113 (Pubitemid 38482164)
25. Zhao, W.Q., Chen, H., Quon, M.J. and Alkon, D.L.W. (2004) Insulin and the insulin receptor in experimental models of learning and memory. Eur. J. Pharmacol. 490, 71-81 (Pubitemid 38482161)
26. Reger, M.A., Watson, G.S., Green, P.S., Baker, L.D., Cholerton, B., Fishel, M.A., Plymate, S.R., Cherrier, M.M., Schellenberg, G.D., Frey, 2nd, W.H. and Craft, S. (2008) Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-β in memory-impaired older adults. J. Alzheimer's Dis. 13, 323-331 (Pubitemid 352039034)
27. Okereke, O.I., Selkoe, D.J., Pollak, M.N., Stampfer, M.J., Hu, F.B., Hankinson, S.E. and Grodstein, F. (2008) A profile of impaired insulin degradation in relation to late-life cognitive decline: a preliminary investigation. Int. J. Geriatr. Psychiatry 24, 177-182
28. Reger, M.A., Watson, G.S., Green, P.S., Wilkinson, C.W., Baker, L.D., Cholerton, B., Fishel, M.A., Plymate, S.R., Breitner, J.C., DeGroodt, W. et al. (2008) Intranasal insulin improves cognition and modulates β-amyloid in early AD. Neurology 70, 440-448
29. Craft, S. (2007) Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr. Alzheimer Res. 4, 147-152
30. Craft, S., Baker, L.D., Green, P.S., Minoshima, S., Cross, D., Montine, T.J., Watson, G.S., Van Fossen, B., Bonner, L., Wilkinson, C.W. et al. (2010) A randomized, placebo-controlled trial of intranasal insulin in amnestic MCI and early Alzheimer's. Alzheimer's Dement. 6 (Suppl.), S587
31. Craft, S., Baker, L.D., Montine, T.J., Minoshima, S., Watson, G.S., Claxton, A., Arbuckle, M., Callaghan, M., Tsai, E., Plymate, S.R. et al. (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 69, 29-38
32. Drucker, D.J. and Nauck, M.A. (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1696-1705 (Pubitemid 46048557)
33. Holst, J.J. (2004) Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Expert Opin. Emerg. Drugs 9, 155-166
34. Campbell, J.E. and Drucker, D.J. (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17, 819-837
35. Madsbad, S., Kielgast, U., Asmar, M., Deacon, C.F., Torekov, S.S. and Holst, J.J. (2011) An overview of once-weekly glucagon-like peptide-1 receptor agonists: available efficacy and safety data and perspectives for the future. Diabetes Obes. Metab. 13, 394-407
36. Elkinson, S. and Keating, G.M. (2013) Lixisenatide: first global approval. Drugs 73, 383-391
37. During, M.J., Cao, L., Zuzga, D.S., Francis, J.S., Fitzsimons, H.L., Jiao, X., Bland, R.J., Klugmann, M., Banks, W.A., Drucker, D.J. and Haile, C.N. (2003) Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. 9, 1173-1179 (Pubitemid 37173702)
38. Perry, T., Holloway, H.W., Weerasuriya, A., Mouton, P.R., Duffy, K., Mattison, J.A. and Greig, N.H. (2007) Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp. Neurol. 203, 293-301 (Pubitemid 46157226)
39. Hamilton, A. and Hölscher, C. (2009) Receptors for the insulin-like peptide GLP-1 are expressed on neurons in the CNS. NeuroReport 20, 1161-1166
40. Perry, T., Haughey, N.J., Mattson, M.P., Egan, J.M. and Greig, N.H. (2002) Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J. Pharmacol. Exp. Ther. 302, 881-888 (Pubitemid 34920207)
41. Sharma, M., Jalewa, J. and Hölscher, C. (2014) Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress. J. Neurochem. 128, 459-471
42. Gault, V. and Hölscher, C. (2008) GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by β-amyloid. Eur. J. Pharmacol. 587, 112-117
43. McClean, P.L., Gault, V.A., Harriott, P. and Hölscher, C. (2010) Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Eur. J. Pharmacol. 630, 158-162
44. Kastin, A.J. and Akerstrom, V. (2003) Entry of exendin-4 into brain is rapid but may be limited at high doses. Int. J. Obes. Relat. Metab. Disord. 27, 313-318
45. Kastin, A.J., Akerstrom, V. and Pan, W. (2002) Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J. Mol. Neurosci. 18, 7-14 (Pubitemid 34252619)
46. Li, Y., Perry, T., Kindy, M.S., Harvey, B.K., Tweedie, D., Holloway, H.W., Powers, K., Shen, H., Egan, J.M., Sambamurti, K. et al. (2009) GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl. Acad. Sci. U.S.A. 106, 1285-1290
47. McClean, P., Parthsarathy, V., Faivre, E. and Hölscher, C. (2011) The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 31, 6587-6594
48. Hunter, K. and Hölscher, C. (2012) Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 13, 33
49. McClean, P.L. and Hölscher, C. (2014) Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. Neuropharmacology 76, 57-67
50. Hölscher, C. (2011) Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. Biochem. Soc. Trans. 39, 891-897
51. Gengler, S., McClean, P., McCurtin, R., Gault, V. and Hölscher, C. (2012) Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol. Aging 33, 265-276
52. Li, Y., Duffy, K., Ottinger, M., Ray, B., Bailey, J., Holloway, H., Tweedie, D., Perry, T., Mattson, M., Kapogiannis, D. et al. (2010) GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J. Alzheimer's Dis. 19, 1205-1219
53. Han, W.-N., Hölscher, C., Yuan, L., Yang, W., Wang, X.-h., Wu, M.-N. and Qi, J.-S. (2013) Liraglutide protects against β-amyloid induced impairment of spatial learning and memory in rats. Neurobiol. Aging 32, 576-588
54. Courrèges, J.P., Vilsboll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Verhoeven, R., Bugáñová, I. and Madsbad, S. (2008) Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet. Med. 25, 1129-1131
55. Perry, T., Lahiri, D.K., Sambamurti, K., Chen, D., Mattson, M.P., Egan, J.M. and Greig, N.H. (2003) Glucagon-like peptide-1 decreases endogenous amyloid-β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron. J. Neurosci. Res. 72, 603-612 (Pubitemid 36578646)
56. Perry, T. and Greig, N.H. (2005) Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr. Alzheimer Res. 2, 377-385 (Pubitemid 40980196)
57. Porter, D.W., Irwin, N., Flatt, P.R., Hölscher, C. and Gault, V.A. (2010) Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice. Eur. J. Pharmacol. 650, 688-693
58. Hamilton, A., Patterson, S., Porter, D., Gault, V.A. and Hölscher, C. (2011) Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J. Neurosci. Res. 89, 481-489
59. Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Ronnholm, H. and Wikstrom, L. (2008) Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J. Neurosci. Res. 86, 326-338 (Pubitemid 351196738)
60. Harkavyi, A., Abuirmeileh, A., Lever, R., Kingsbury, A.E., Biggs, C.S. and Whitton, P.S. (2008) Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J. Neuroinflammation 5, 19
61. Pressley, J.C., Louis, E.D., Tang, M.X., Cote, L., Cohen, P.D., Glied, S. and Mayeux, R. (2003) The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology 60, 87-93 (Pubitemid 36070650)
62. Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A. et al. (2013) Exenatide and the treatment of patients with Parkinson's disease. J. Clin. Invest. 123, 2730-2736
63. Cotman, C.W., Berchtold, N.C. and Christie, L.A. (2007) Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci. 30, 464-472 (Pubitemid 47374831)
64. Bradbury, J. (2005) Hope for AD with NGF gene-therapy trial. Lancet Neurol. 4, 335
65. Azzouz, M., Ralph, G.S., Storkebaum, E., Walmsley, L.E., Mitrophanous, K.A., Kingsman, S.M., Carmeliet, P. and Mazarakis, N.D. (2004) VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429, 413-417 (Pubitemid 38715132)
66. Gregory-Evans, K., Chang, F., Hodges, M.D. and Gregory-Evans, C.Y. (2009) Ex vivo gene therapy using intravitreal injection of GDNF-secreting mouse embryonic stem cells in a rat model of retinal degeneration. Mol. Vis. 15, 962-973
67. Hölscher, C. (2012) Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS Drugs 26, 871-882